Announcements Trials
Browse Landscape

Phase

Phase 4 2Phase 2/3 2Phase 3 1Phase 2 1

Status

Unknown 1Completed 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1Breast 1

Conditions

Peripheral Nervous System Diseases 1Gastrointestinal Neoplasms 1Cognitive Dysfunction 1Cardiotoxicity 1Breast Neoplasms 1

Interventions

Cisplatin 54Cyclophosphamide 42Fluorouracil 41Oxaliplatin 36Capecitabine 35Docetaxel 34Gemcitabine 32Drug Therapy 32Radiotherapy 31Paclitaxel 25Dexamethasone 23Carboplatin 23Leucovorin 21Etoposide 17Doxorubicin 17Cytarabine 17apatinib 16Methotrexate 16Magnetic Resonance Spectroscopy 14Radiation 13Epirubicin 13Busulfan 13Bevacizumab 13Surgical Procedures, Operative 12Neoadjuvant Therapy 12Letrozole 12Decitabine 12Saline Solution 11Irinotecan 11venetoclax 10

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2/3 × OTHER × Silymarin × Clear all
NCT05595109 2022-10-26

Role of Silymarin in Chemotherapy Toxicity and Cognition Improvement in Breast Cancer Patients

Tanta University

Phase 2/3 Unknown
56 enrolled
Breast

Breast Neoplasms, Peripheral Nervous System Diseases, Cognitive Dysfunction, Cardiotoxicity

NCT01829178 2015-05-13

Evaluation of Effects of Silymarin on Cisplatin Induced Nephrotoxicity in Upper Gastrointestinal Adenocarcinoma

Tehran University of Medical Sciences

Phase 2/3 Completed
30 enrolled
Gastrointestinal

Gastrointestinal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡